关键词： 血栓；溶栓药物；半衰期；分子突变体；嵌合体[gap=942]Key words: thrombus; thrombolytic drug; half-life; molecular mutant; chimera
基于6个网页-相关网页
Conclusion:Both fibrinolytic enzyme and urokinase were effective , reliable thrombolytic drugs in the treatment of ADVT,. However , fibrinolytic enzyme showed significantly better security than that of urokinase in thrombolytic therapy.
结论:蛇毒纤溶酶和尿激酶都是治疗急性下肢深静脉形成疗效肯定、安全的溶栓药物,蛇毒纤溶酶安全性高于尿激酶。
参考来源 - 蛇毒纤溶酶与尿激酶治疗急性下肢深静脉血栓形成临床对比观察Recently, a series of researches to explore the gene sequence and the physiological and bio-chemical characteristics have been done, which showed that Nattokinase can be a new type of medicine to cure lysis thrombus.
近年来，国内外学者对纳豆激酶的基因序列和生理生化特性进行的一系列研究表明，纳豆激酶可被开发成为一种新型的溶栓药物。
参考来源 - 纳豆激酶基因的克隆及表达研究AT not only can directly cleave cross-linked fibrin,but also can activate plasminogen to plasmin. So AT will be useful as a new type potent ideal thrombolytic agent.
AT对纤维蛋白有直接的降解作用,有望成为一种新型的溶栓药物。
参考来源 - 枯草杆菌安舒克栓酶随机突变、筛选及其部分性质研究·2,447,543篇论文数据，部分数据来源于NoteExpress
目的探讨经脑动脉内注溶栓药物治疗急性闭塞性脑血管病的临床效果。
Objective To evaluate the value of intra arterial thrombolytic therapy in the treatment of acute occlusive cerebral disease.
随着急性心肌梗死发病率的逐年上升，新的溶栓药物正在不断的研制中。
With the increase in the morbidity of acute myocardial infarction, new thrombolytics are continually developed.
目的：介绍急性心肌梗死溶栓药物的研发进展，并评价其临床疗效和安全性。
OBJECTIVE: To introduce the research and development of thrombolytic drugs for AMI, and evaluate their clinical efficacy and safety.
应用推荐